Why a failed experiment took fifteen years to become a Nobel Prize

In 1995, in a lab in Berkeley, California, immunologist Jim Allison injected a dozen mice with cancer tumors and then gave them an experimental antibody he had spent years developing. He had a theory: T-cells, the immune system's killers, carry a kind of built-in brake that stops them from attacking healthy tissue, and cancer cells had learned to hide behind that brake. If he could block the brake instead, the immune system might finally recognize the cancer as the threat it was.

When Allison checked on the mice days later, their tumors had grown bigger. He assumed the experiment had failed. Two days after that, he checked again. Almost all the tumors had vanished.

That should have been the end of the story, the moment where the world rushes in. Instead, it was the start of fifteen more years in which, as Admiral William H. McRaven recounts, Allison was told no by nearly everyone who mattered: no funding, no interest in years of clinical trials, no confidence the science was strong enough. Pharmaceutical companies, burned before by promising drugs that went nowhere, weren't eager to bet again.

Allison kept working anyway. Asked later what the most important thing he'd learned in the lab actually was, he didn't point to a technique or an insight. He said it was how important it is simply to persevere, to not be so disappointed that you stop, to just keep working. Eventually a pharmaceutical company agreed to fund human trials. One of the earliest patients was a twenty-three-year-old woman whose melanoma had already spread to her liver and brain, and who had run out of other options. Within a week of receiving Allison's drug, her brain scan showed the tumor was gone. Fourteen years later, McRaven notes, she remains cancer free.

In 2011 the FDA approved the drug, ipilimumab. Over a million patients have since received it. In 2018, Allison walked onto a stage in Stockholm to accept the Nobel Prize in Medicine, a year after he'd fulfilled a much smaller dream, playing harmonica onstage with Willie Nelson.

McRaven's point in telling this story is not that talent eventually wins out, since Allison had plenty of it from the start and it still took fifteen years of being told no. His point is that the gap between a good idea and a working cure is filled entirely with the willingness to keep going after everyone credible has told you to stop, one experiment, one rejected grant, one skeptical conference at a time.

Pick the one goal in your life right now that has already collected a string of no's, and instead of measuring how far you still have to go, identify only the next single action in front of you, the one email, the one draft, the one attempt. Do that one thing this week without projecting how many more rejections might be coming, because thinking too far ahead is exactly what breaks people's resolve before it needs to. When the next no arrives, and it will, give yourself permission to be disappointed briefly, then return to the same question: what is the next single step. Keep repeating that cycle rather than waiting for a green light from anyone else, since the people who eventually succeed are usually the ones who simply never stopped taking the next step.